Current report
Open the filing on sec.gov
Propanc Biopharma, Inc. (PPCB)
Nasdaq: PPCB · Pharmaceutical Preparations · Camberwell, Victoria, AU · filing with the SEC since 2011
The companyfiscal 2026, as filed
Revenuen/a
Net income-$18.9M+68.0%
Earnings per share$-17.62+95.3%
Operating cash flow-$5.7M-1302.5%
Cashn/a
Debtn/a
Shareholders’ equity$9.4M-32.4%
Shares, diluted1,123,709+608.0%
Return on equity-200.6%
The recordfrom its filings
Filings in 202633
Newest filingOct 29 · 8-K
Annual reportSep 25, 2026
Quarterly reportMay 14, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$18.9MCash from operations -$5.7Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Information statement
Open the filing on sec.gov
Preliminary information statement
Open the filing on sec.gov
Listing registration
Open the filing on sec.gov
Annual report
Open the filing on sec.gov
Information statement
Open the filing on sec.gov
Preliminary information statement
Open the filing on sec.gov
Registration effective
Open the filing on sec.gov
Listing registration
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.